<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordsOutput><serviceExecutionTime>330</serviceExecutionTime><Drug id="5530"><DrugName>coluracetam</DrugName><DrugNamesKey><Name id="42934270">coluracetam</Name></DrugNamesKey><DrugSynonyms><Name><Value>MKC-231</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>neurons growth promoting compound (major depressive disorder/anxiety), BrainCells</Value></Name><Name><Value>BCI-540</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>high-affinity choline uptake facilitator (depression/ anxiety), BrainCells</Value></Name><Name><Value>high-affinity choline uptake facilitator (CNS disorders), Mitsubishi</Value></Name><Name><Value>coluracetam</Value><Types><Type>INN</Type></Types></Name><Name><Value>135463-81-9</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="20983">Mitsubishi Pharma Corp</CompanyOriginator><CompaniesSecondary><Company id="1015253">BrainCells Inc</Company><Company id="1035060">Mitsubishi Tanabe Pharma Corp</Company><Company id="18229">Mitsubishi-Tokyo Pharmaceuticals Inc</Company><Company id="20300">Takeda Pharmaceutical Co Ltd</Company><Company id="20983">Mitsubishi Pharma Corp</Company></CompaniesSecondary><CrossReferences><SourceEntity id="5530" type="Drug"><TargetEntity id="438526" type="siDrug"></TargetEntity></SourceEntity><SourceEntity id="1015253" type="Company"><TargetEntity id="4297109341" type="organizationId">BrainCells Inc</TargetEntity></SourceEntity><SourceEntity id="1035060" type="Company"><TargetEntity id="4295878022" type="organizationId">Mitsubishi Tanabe Pharma Corp</TargetEntity></SourceEntity><SourceEntity id="18229" type="Company"><TargetEntity id="4295878585" type="organizationId">Tokyo Tanabe Co Ltd</TargetEntity></SourceEntity><SourceEntity id="20300" type="Company"><TargetEntity id="4295877353" type="organizationId">Takeda Pharmaceutical Co Ltd</TargetEntity></SourceEntity><SourceEntity id="20983" type="Company"><TargetEntity id="4295878530" type="organizationId">Mitsubishi Pharma Corp</TargetEntity></SourceEntity><SourceEntity id="14" type="ciIndication"><TargetEntity id="G30" type="ICD10"/><TargetEntity id="331.0" type="ICD9"/><TargetEntity id="10012271" type="MEDDRA"/><TargetEntity id="D000544" type="MeSH"/><TargetEntity id="-1268969445" type="omicsDisease"/><TargetEntity id="101" type="siCondition"/></SourceEntity><SourceEntity id="15" type="ciIndication"><TargetEntity id="10001949" type="MEDDRA"/><TargetEntity id="D000647" type="MeSH"/><TargetEntity id="-1501831747" type="omicsDisease"/><TargetEntity id="107" type="siCondition"/></SourceEntity><SourceEntity id="25" type="ciIndication"><TargetEntity id="10057666" type="MEDDRA"/><TargetEntity id="D001008" type="MeSH"/><TargetEntity id="-1384065283" type="omicsDisease"/><TargetEntity id="30" type="siCondition"/></SourceEntity><SourceEntity id="299" type="ciIndication"><TargetEntity id="F20" type="ICD10"/><TargetEntity id="10039626" type="MEDDRA"/><TargetEntity id="D012559" type="MeSH"/><TargetEntity id="-729613619" type="omicsDisease"/><TargetEntity id="65" type="siCondition"/></SourceEntity><SourceEntity id="65" type="ciIndication"><TargetEntity id="D020521" type="MeSH"/><TargetEntity id="-1815339002" type="omicsDisease"/><TargetEntity id="93" type="siCondition"/></SourceEntity><SourceEntity id="93" type="ciIndication"><TargetEntity id="10012378" type="MEDDRA"/><TargetEntity id="D003863" type="MeSH"/><TargetEntity id="-508468160" type="omicsDisease"/><TargetEntity id="53" type="siCondition"/></SourceEntity><SourceEntity id="1559" type="Action"><TargetEntity id="5742" type="Mechanism">AMPA Receptor Positive Allosteric Modulators</TargetEntity><TargetEntity id="157" type="Mechanism">AMPA Receptor Agonists</TargetEntity></SourceEntity><SourceEntity id="2518" type="Action"><TargetEntity id="782" type="Mechanism">Cholinergic Channel Activators</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="C2">Phase 2 Clinical</PhaseTerminated><IndicationsSecondary><Indication id="14">Alzheimers disease</Indication><Indication id="15">Amnesia</Indication><Indication id="25">Anxiety disorder</Indication><Indication id="299">Schizophrenia</Indication><Indication id="65">Stroke</Indication><Indication id="93">Depression</Indication></IndicationsSecondary><ActionsPrimary><Action id="1559">AMPA receptor agonist</Action></ActionsPrimary><ActionsSecondary><Action id="2942">Anxiolytic</Action><Action id="2518">Choline uptake stimulator</Action><Action id="1615">Neuroprotectant</Action><Action id="284">Nootropic agent</Action><Action id="2941">Antidepressant</Action><Action id="2943">Antipsychotic</Action></ActionsSecondary><Technologies><Technology id="762">Small molecule therapeutic</Technology><Technology id="585">Oral formulation</Technology></Technologies><EphmraCodes><Ephmra><Code>N5A</Code><Name>ANTIPSYCHOTICS</Name></Ephmra><Ephmra><Code>N5C</Code><Name>TRANQUILLISERS</Name></Ephmra><Ephmra><Code>N6A</Code><Name>ANTI-DEPRESSANTS AND MOOD STABILISERS</Name></Ephmra><Ephmra><Code>N6D</Code><Name>NOOTROPICS</Name></Ephmra></EphmraCodes><LastModificationDate>2017-11-29T16:04:45.000Z</LastModificationDate><ChangeDateLast>2016-09-29T00:00:00.000Z</ChangeDateLast><AddedDate>1996-02-16T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="1015253" linkType="Company"&gt;BrainCells Inc&lt;/ulink&gt; (BCI), under license from  &lt;ulink linkID="1035060" linkType="Company"&gt;Mitsubishi Tanabe Pharma &lt;/ulink&gt;(formerly &lt;ulink linkID="20983" linkType="Company"&gt;Mitsubishi Pharma&lt;/ulink&gt;), was developing coluracetam (BCI-540, MKC-231), an acylaminopyridine high-affinity choline uptake facilitator (HACU) and AMPA potentiator that promotes neuron growth, for the potential oral treatment of major depressive disorder (MDD) and anxiety disorder [&lt;ulink linkID="810268" linkType="Reference"&gt;810268&lt;/ulink&gt;], [&lt;ulink linkID="344071" linkType="reference"&gt;344071&lt;/ulink&gt;],   [&lt;ulink linkID="836299" linkType="Reference"&gt;836299&lt;/ulink&gt;].  In April 2008, BCI began a phase IIa trial for depression with anxiety [&lt;ulink linkID="897966" linkType="Reference"&gt;897966&lt;/ulink&gt;]; in  November 2011, development was ongoing [&lt;ulink linkID="1242464" linkType="Reference"&gt;1242464&lt;/ulink&gt;]. However,  by May 2012, the agreement between BrainCells and Mitsubishi Tanabe was terminated and it was presumed that development of the agent had discontinued  [&lt;ulink linkID="1288966" linkType="Reference"&gt;1288966&lt;/ulink&gt;]. In  November 2011,  the company was seeking to outlicense the drug  [&lt;ulink linkID="1242464" linkType="Reference"&gt;1242464&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Mitsubishi was previously developing the drug (as MK-231) for CNS disorders, including Alzheimer's disease (AD). In November 1999, it was in Japanese phase II trials   [&lt;ulink linkID="371091" linkType="reference"&gt;371091&lt;/ulink&gt;]. By March 2001, phase II studies were underway in the US and Europe [&lt;ulink linkID="400514" linkType="reference"&gt;400514&lt;/ulink&gt;]. In May 2003, only the US phase II trial was listed as ongoing  [&lt;ulink linkID="491163" linkType="reference"&gt;491163&lt;/ulink&gt;]; this was still the case  in May 2004 [&lt;ulink linkID="538366" linkType="reference"&gt;538366&lt;/ulink&gt;], [&lt;ulink linkID="520195" linkType="reference"&gt;520195&lt;/ulink&gt;]. However, in August 2006, Mitsubishi  disclosed that development of the drug was discontinued  since endpoints in phase II  trials were not met   [&lt;ulink linkID="683416" linkType="Reference"&gt;683416&lt;/ulink&gt;], [&lt;ulink linkID="810268" linkType="Reference"&gt;810268&lt;/ulink&gt;]. Other indications such as amnesia, stroke and  schizophrenia were explored  [&lt;ulink linkID="344071" linkType="Reference"&gt;344071&lt;/ulink&gt;], [&lt;ulink linkID="400514" linkType="Reference"&gt;400514&lt;/ulink&gt;], [&lt;ulink linkID="423717" linkType="Reference"&gt;423717&lt;/ulink&gt;], [&lt;ulink linkID="810852" linkType="Reference"&gt;810852&lt;/ulink&gt;], but no developments had been reported for some time and in May 2008, the company listed development of the drug as being overseas by BrainCells [&lt;ulink linkID="905882" linkType="Reference"&gt;905882&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;ulink linkID="20300" linkType="Company"&gt;Takeda&lt;/ulink&gt; was a collaborator on the development of the drug   [&lt;ulink linkID="344071" linkType="reference"&gt;344071&lt;/ulink&gt;], [&lt;ulink linkID="348496" linkType="reference"&gt;348496&lt;/ulink&gt;]; however, by July 2002, the drug was no longer listed on its pipeline [&lt;ulink linkID="459802" linkType="reference"&gt;459802&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Summary&gt;</value></Summary><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;In August 2006, BCI  planned to begin phase II MDD and anxiety trials  in 2007 [&lt;ulink linkID="683416" linkType="Reference"&gt;683416&lt;/ulink&gt;], [&lt;ulink linkID="810268" linkType="Reference"&gt;810268&lt;/ulink&gt;].  In March 2008, phase II trials were to start in 2008 [&lt;ulink linkID="884296" linkType="Reference"&gt;884296&lt;/ulink&gt;]. In April 2008, BCI began a phase IIa trial  (NCT00621270; BCI-540-CL-001).   The 12-week, Canadian, 90-patient, randomized, double-blind, placebo-controlled study was to evaluate the safety, efficacy and tolerability of 80 mg of coluracetam given once or three times daily. The primary endpoints were change in inventory of depressive symptomatology-clinician version (IDS-C30) and the Hamilton rating scale for anxiety (HAM-A) scores at week six. Secondary endpoints included safety measures. At that time, enrollment was expected to be completed by the end of 2008 [&lt;ulink linkID="897994" linkType="Reference"&gt;897994&lt;/ulink&gt;], [&lt;ulink linkID="897966" linkType="Reference"&gt;897966&lt;/ulink&gt;]. In March 2009, recruitment of subjects was ongoing [&lt;ulink linkID="897994" linkType="Reference"&gt;897994&lt;/ulink&gt;]. By November 2009, enrollment was complete and results were expected in early 2010 [&lt;ulink linkID="1088872" linkType="Reference"&gt;1088872&lt;/ulink&gt;]. In June 2010, results showed that  there was no benefit of BCI-540 on Hamilton rating scale (HAM)-A or HAM-D compared to placebo, at week 6,  in the overall population .  A total of 36% responders were seen in the coluracetam tid group, compared to 19% in the placebo group. Within this group, depression symptoms of those with co-morbid general anxiety disorder improved by 12.2 points on HAM-D compared to 5.5 points in the placebo group. BCI-540 was well tolerated, with a side effect profile similar to placebo [&lt;ulink linkID="1242471" linkType="Reference"&gt;1242471&lt;/ulink&gt;]. In November 2010, data from the trial were presented at the 40th SFN Meeting in San Diego, CA. In 101 evaluable patients, BCI-540 was demonstrated to have no significant advantage over placebo on change in depression or anxiety measures. However, both BCI-540 did induce a higher response rate as measured using the 17-item HAM-D17 compared with the placebo group. In a subset of patients (n = 31) with concomitant GAD and receiving BCI-540 tid, the change from baseline demonstrated a large treatment effect size on all clinician ratings compared with placebo, and this was statistically significant for the HAM-D17 scale. Response rates over 6 weeks were higher on HAM-D17 and HAM-A for both the BCI-540 regimens in the MDD with comorbid GAD group [&lt;ulink linkID="1145602" linkType="Reference"&gt;1145602&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;By August 2006, the drug had failed to meet its efficacy endpoints in a Mitsubishi phase II trial. However, the drug was shown to be safe  [&lt;ulink linkID="683416" linkType="Reference"&gt;683416&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2007, it was reported that BCI expected to commence phase I trials 'shortly' [&lt;ulink linkID="842006" linkType="Reference"&gt;842006&lt;/ulink&gt;]&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;By May 2008, in vitro studies conducted in AF64A treated rats which were administered with 1 and 3 mg/kg of the drug orally for 8 days repeatedly and tested for learning impairment in the water-maze task at 1, 24 28 and 72 h after the last dose. The results demonstrated that the drug had shown long-lasting procongnitive effects by enhancing HACU [&lt;ulink linkID="926248" linkType="Reference"&gt;926248&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By May 2008, studies conducted in the hippocampus of normal and AF64A-treated rats showed that the drug (10(-8) and 10(-7) M) was able to reverse the decrease in both HACU and ACH release. Further in vivo microdialysis studies conducted in AF64A-treated rats showed that the drug (10 mg/kg, po) significantly reversed reduction of basal ACh concentrations [&lt;ulink linkID="926203" linkType="Reference"&gt;926203&lt;/ulink&gt;].&lt;br&gt;&lt;/br&gt;&lt;br&gt;&lt;/br&gt;By April 2007, preclinical studies of coluracetam  were carried out at the Department of Neuropsychiatry at &lt;ulink linkID="25971" linkType="Company"&gt;Tottori University&lt;/ulink&gt;, Japan, evaluating its effects on the behavioral and cellular changes observed in rats after exposure to phencyclidine (PCP). Increased locomotion was seen after an acute PCP or cocaine challenge, and decreased locomotion was observed following a carbachol-challenge. The locomotor changes were antagonized significantly by coluracetam when challenged with cocaine or carbachol, but no effect was seen with in the case of PCP. In an object recognition test, coluracetam antagonized PCP-induced cognitive deficits. In addition, repeated exposure with PCP caused a decrease in the  number of choline acetyltransferase (ChAT)-positive cells in the medial septum, which was significantly antagonized by coluracetam, and an increase in dynorphin A expression in the ventral striatum, which was unaffected by coluracetam. The results suggested the use of coluracetam in the treatment of schizophrenia [&lt;ulink linkID="810852" linkType="Reference"&gt;810852&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In 1999, coluracetam showed significant improvement in a number of models of learning and memory disorders in rats. The mechanism of action of coluracetam appears to be improvement of reduced acetylcholine nerve activity. Restoration of destruction to the basilar region of the forebrain was observed 24 h following administration of coluracetam, and acetylcholine (ACh) content in the cerebral cortex increased [&lt;ulink linkID="344071" linkType="reference"&gt;344071&lt;/ulink&gt;].  At that time, coluracetam had been observed to promote uptake of high-affinity choline in the nerve terminals and activates ACh nerves by increasing acetylcholine synthesis [&lt;ulink linkID="344071" linkType="reference"&gt;344071&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In 1997,  coluracetam was shown to ameliorate the learning impairment of AF64-A-treated rats in Morris's water maze. Repeated administration of coluracetam improved memory deficits in passive avoidance tests and restored decrease in ACh content in rats with basal forebrain lesions produced by bilateral ibotenic acid injections [&lt;ulink linkID="249846" linkType="reference"&gt;249846&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;In August 2006, BrainCells licensed   coluracetam from Mitsubishi [&lt;ulink linkID="683416" linkType="Reference"&gt;683416&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In 1999, it was reported that &lt;ulink linkID="20300" linkType="Company"&gt;Takeda&lt;/ulink&gt; was codeveloping coluracetam in collaboration with Mitsubishi-Tokyo (now Mitsubishi Tanabe) [&lt;ulink linkID="344071" linkType="reference"&gt;344071&lt;/ulink&gt;]. However, by May 2003, Mitsubishi did not list Takeda as a partner on this program, and it was presumed that the agreement had terminated [&lt;ulink linkID="491163" linkType="reference"&gt;491163&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><ExpertReview>&lt;para&gt;&lt;subtitle&gt;Yun Chen, NINDS, Bethesda, MD, USA&lt;/subtitle&gt;&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;28 May 2000&lt;/subtitle&gt;&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Introduction&lt;/subtitle&gt;MCK-231 is a acylaminopyridine high affinity choline uptake (HACU) facilitator in phase II clinical trials [&lt;ulink linkType="reference" linkID="348496"&gt;348496&lt;/ulink&gt;] [&lt;ulink linkType="reference" linkID="350686"&gt;350686&lt;/ulink&gt;] [&lt;ulink linkType="reference" linkID="355364"&gt;355364&lt;/ulink&gt;] as a memory enhancer/nootropic agent for the potential treatment of Alzheimer's disease (AD) and amnesia [&lt;ulink linkType="reference" linkID="165246"&gt;165246&lt;/ulink&gt;] [&lt;ulink linkType="reference" linkID="344071"&gt;344071&lt;/ulink&gt;]. AD is the most prevalent of the neurodegerative diseases and main cause of dementia in elderly people [&lt;ulink linkType="reference" linkID="181350"&gt;181350&lt;/ulink&gt;]. Deficient cholinergic function is a consistent feature of AD, and has been shown to be most closely correlated with the severity of cognitive impairment in senile dementia and AD [&lt;ulink linkType="reference" linkID="198412"&gt;198412&lt;/ulink&gt;]. HACU is thought to be the rate-limiting step in acetylcholine (ACh) synthesis in the neuron, and the velocity of choline transport correlates with the activity of cholinergic neurons. In the AD brain, reduction in HACU will cause decreased synthesis and release of ACh [&lt;ulink linkType="reference" linkID="226209"&gt;226209&lt;/ulink&gt;]. The enhancement of HACU and the improvement of reduced ACh nerve activity in the brain by &lt;ulink linkType="Drug" linkID="5530"&gt;MKC-231&lt;/ulink&gt; may therefore ameliorate cholinergic deficits and lead to symptomatic improvement of AD through an increase in ACh synthesis and release [&lt;ulink linkType="reference" linkID="181350"&gt;181350&lt;/ulink&gt;] [&lt;ulink linkType="reference" linkID="344071"&gt;344071&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Synthesis and SAR&lt;/subtitle&gt;&lt;ulink linkType="Drug" linkID="5530"&gt;MKC-231&lt;/ulink&gt;, [2-(2-oxypyrrolidin-1-yl)-N-(2,3-dimethyl-5,6,7,8-tetrahydrofuro[2,3-b]quindin-4-yl)acetoamide], is a newly synthetized tetrahydrofuro-quinoline and a member of a novel class of nootropic agents [&lt;ulink linkType="reference" linkID="198412"&gt;198412&lt;/ulink&gt;]. The acylated derivatives of tetrahydroacridine (THA), which contains 4-acylaminopyridine, have been shown to have HACU improvement activity. Their activities dependent on the carbon chain length or proper functional group(s) of the N-acyl substituent. In the alkylcarbonyl series, optimum activity was obtained with the N-propylcarbonyl derivatives. Increase or decrease in the carbon chains or branching of the carbon chain might reduce the activity. Azasubstitution of the corresponding alkylcarbonyl derivatives might produce undesirable results. Also, the carboxymethylaminoacetyl derivatives did not show any HACU improvement activity. &lt;/para&gt;&lt;para&gt;In the cyclic series, the carbonyl group(s) or double bonds should also be necessary to improve the potency. In contrast, the 2-oxo-1-pyrrolidine-acetyl derivative had the HACU improment activity only at 100 nM. Azasubstitution at the C3 position of the ring might maintain the activity but the introduction of the second carbonyl group to the ring caused different results. Expansion in ring or decarbonylation produced unsatisfying results. Methyl substitution at the C5 position of the ring might produce reduced activity as compared with that of the unsubstituted derivative. Therefore, the moderate bulkiness of the N-acyl substituent and the introduction of carbonyl group or double bond to the five-membered ring, should be necessary to produce HACU improvement activities [&lt;ulink linkType="reference" linkID="181346"&gt;181346&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;To obtain &lt;ulink linkType="Drug" linkID="5530"&gt;MKC-231&lt;/ulink&gt; (the structural distinct compound with high HACU improvement activity), the ring structure and acyl moiety of N-propylcarbonyl-tetrahydroaminoacridine from 4-acylaminopyridine derivatives were modified. The left and right parts of the tricyclic structure were fixed to the phenyl ring and the cyclohexane ring, respectively. The transformation of the two rings fused to 4-aminopyridine followed by optimization of the acyl moiety led to some active compounds. Among them, &lt;ulink linkType="Drug" linkID="5530"&gt;MKC-231&lt;/ulink&gt; showed the highest HACU improvement activity (55% of HACU value at 10 nM, 72% at 100 nM and 64% at 1 microM, respectively) [&lt;ulink linkType="reference" linkID="181350"&gt;181350&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Pharmacology&lt;/subtitle&gt;&lt;ulink linkType="Drug" linkID="5530"&gt;MKC-231&lt;/ulink&gt; protected cortical neurons against glutamate cytoxicity by the enhancement of choline uptake function. Exposure of cortical cultures obtained from fetal rats to &lt;ulink linkType="Drug" linkID="5530"&gt;MKC-231&lt;/ulink&gt; for 21 to 24 h ameliorated glutamate cytotoxicity in a concentration-dependent manner [&lt;ulink linkType="reference" linkID="158589"&gt;158589&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="289268"&gt;289268&lt;/ulink&gt;]. &lt;ulink linkType="Drug" linkID="5530"&gt;MKC-231&lt;/ulink&gt; also reduced ethylcholine mustard aziridinium ion (AF64A)-induced cytotoxicity. The protective effect of &lt;ulink linkType="Drug" linkID="5530"&gt;MKC-231&lt;/ulink&gt; in glutamate cytotoxicity was potentiated by choline [&lt;ulink linkType="reference" linkID="158589"&gt;158589&lt;/ulink&gt;]. In another study designed to investigate cytoxicity, &lt;ulink linkType="Drug" linkID="5530"&gt;MKC-231&lt;/ulink&gt; (10 mM) reduced cytotoxicity induced by ionomycin, a calcium ionophore, but didn't affect the cytotoxicity induced by S-nitrosocysteine, a nitric oxide (NO) donor. &lt;/para&gt;&lt;para&gt; &lt;ulink linkType="Drug" linkID="5530"&gt;MKC-231&lt;/ulink&gt; protects against glutamate neurotoxicity by suppressing the NO formation triggered by Ca2+-influx [&lt;ulink linkType="reference" linkID="289268"&gt;289268&lt;/ulink&gt;]. &lt;ulink linkType="Drug" linkID="5530"&gt;MKC-231&lt;/ulink&gt; (10 mg/kg po) facilitated ACh release from the hippocampus in the study using in vivo microdialysis [&lt;ulink linkType="reference" linkID="158595"&gt;158595&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="249846"&gt;249846&lt;/ulink&gt;]. Incubation of the hippocampal synaptosomes with &lt;ulink linkType="Drug" linkID="5530"&gt;MKC-231&lt;/ulink&gt; caused an increase in synaptosomal HACU and delayed the gradual decline of fractional ACh release evoked by high K+ (35 mM) stimulation [&lt;ulink linkType="reference" linkID="249846"&gt;249846&lt;/ulink&gt;]. The effect of &lt;ulink linkType="Drug" linkID="5530"&gt;MKC-231&lt;/ulink&gt; on ACh release was examined in vitro and in vivo in AF64A-treated rats. &lt;ulink linkType="Drug" linkID="5530"&gt;MKC-231&lt;/ulink&gt; has been observed to increase basal extracellular ACh concentration in the hippocampus of AF64A-treated rats by enhancing HACU and improving ACh release in a dose-dependent manner [&lt;ulink linkType="reference" linkID="249846"&gt;249846&lt;/ulink&gt;]. The addition of &lt;ulink linkType="Drug" linkID="5530"&gt;MKC-231&lt;/ulink&gt; (1 microM) into incubation medium with 3H-choline restored the attenuation of HACU by 44% and antagonized a reduction in ACh release by 43%. &lt;/para&gt;&lt;para&gt;HACU improvement values of &lt;ulink linkType="Drug" linkID="5530"&gt;MKC-231&lt;/ulink&gt; were measured in the hippocampal synaptosomes of AF64A-treated rats. &lt;ulink linkType="Drug" linkID="5530"&gt;MKC-231&lt;/ulink&gt; produced high HACU improvement activity even at low concentrations (55% at 10 nM, 72% at 100 nM and 64% at 1 microM, respectively, as compared with other N-acyl derivatives) [&lt;ulink linkType="reference" linkID="181350"&gt;181350&lt;/ulink&gt;]. &lt;ulink linkType="Drug" linkID="5530"&gt;MKC-231&lt;/ulink&gt; has effects on AF64A-induced reduction of HACU and impairment of water maze performance in rats. The icv injection of AF64A induced a decrease in ChAT activity, HACU, and ACh release and level in the hippocampus in a concentration-dependent manner. This reduction in cholinergic activity induced by AF64A was associated with impaired memory and cognitive functions. &lt;ulink linkType="Drug" linkID="5530"&gt;MKC-231&lt;/ulink&gt; (0.3 to 3 mg/kg po) inhibited reduction of HACU induced by AF64A, and improved impairment of spatial learning performance in Morris water maze in rats [&lt;ulink linkType="reference" linkID="162447"&gt;162447&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="168372"&gt;168372&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In a comparative study of &lt;ulink linkType="Drug" linkID="5530"&gt;MKC-231&lt;/ulink&gt; and the AChE inhibitor, &lt;ulink linkType="Drug" linkID="4509"&gt;tacrine&lt;/ulink&gt;, on neurochemistry and cognitive function in AF64A-treated rats, &lt;ulink linkType="Drug" linkID="5530"&gt;MKC-231&lt;/ulink&gt; (0.1 nM to 1 microM) increased HACU when it was incubated with the hippocampal synaptosomes, but did not affect the AChE activity, 3H-QNB binding and 3H-pirenzepine binding. Oral administration of &lt;ulink linkType="Drug" linkID="5530"&gt;MKC-231&lt;/ulink&gt; (1 to 10 mg/kg) also improved the learning deficits in Morris water maze. However, &lt;ulink linkType="Drug" linkID="4509"&gt;tacrine&lt;/ulink&gt; failed to ameliorate the learning deficits in AF64A-treated rats [&lt;ulink linkType="reference" linkID="226209"&gt;226209&lt;/ulink&gt;]. Moreover, repeated administrations (once a day for 8 days) of &lt;ulink linkType="Drug" linkID="5530"&gt;MKC-231&lt;/ulink&gt; (1.1 and 10 mg/kg po) improved memory deficits in passive avoidance task, and restored a decrease in ACh level in the cortex of basal forebrain-lesioned rats induced by ibotenic acid [&lt;ulink linkType="reference" linkID="247205"&gt;247205&lt;/ulink&gt;]. In AF64A-treated mice, &lt;ulink linkType="Drug" linkID="5530"&gt;MKC-231&lt;/ulink&gt; also improved retrieval deficits in long-term memory at doses of 0.1 and 0.3 mg/kg, and reversed the hippocampal ACh depletion at doses of 0.3, 1.0 and 3.0 mg/kg [&lt;ulink linkType="reference" linkID="175898"&gt;175898&lt;/ulink&gt;]. The effects of acute and chronic administration of &lt;ulink linkType="Drug" linkID="5530"&gt;MKC-231&lt;/ulink&gt; on working memory deficits and on the hippocampus ACh depletion were studied in T-maze tasks in AF64A-treated mice. In acute experiments, &lt;ulink linkType="Drug" linkID="5530"&gt;MKC-231&lt;/ulink&gt; (0.3 mg/kg po) improved memory deficits induced by AF64A but did not reverse the ACh depletion in the hippocampus. However, in chronic experiments, &lt;ulink linkType="Drug" linkID="5530"&gt;MKC-231&lt;/ulink&gt; had effect not only on improving memory deficits, but also on reversing the ACh depletion at all doses tested (0.3, 1.0 or 3.0 mg/kg po once daily for 11 days) [&lt;ulink linkType="reference" linkID="160499"&gt;160499&lt;/ulink&gt;], [&lt;ulink linkType="reference" linkID="198412"&gt;198412&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Metabolism&lt;/subtitle&gt;No data are currently available.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Toxicity&lt;/subtitle&gt;The lethal dose of &lt;ulink linkType="Drug" linkID="5530"&gt;MKC-231&lt;/ulink&gt; has been reported to be over 1000 mg/kg po in rats [&lt;ulink linkType="reference" linkID="226209"&gt;226209&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Clinical Development &lt;/subtitle&gt;&lt;subtitle&gt;Phase I&lt;/subtitle&gt;No data are currently available.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;No data are currently available.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Side-effects and Contraindications&lt;/subtitle&gt;&lt;ulink linkType="Drug" linkID="5530"&gt;MKC-231&lt;/ulink&gt; did not cause tremor, salivation or hypothermia even at a dose of 100 mg/kg po in rats [&lt;ulink linkType="reference" linkID="226209"&gt;226209&lt;/ulink&gt;]. Administration of &lt;ulink linkType="Drug" linkID="5530"&gt;MKC-231&lt;/ulink&gt; (50 and 500 nmol icv) caused a slight, but significant increase in glucose level of the hepatic venous. The systemic administration of &lt;ulink linkType="Drug" linkID="5530"&gt;MKC-231&lt;/ulink&gt; (50 and 500 nmol iv) had no significant effect on the plasma concentration of glucose. The potency of &lt;ulink linkType="Drug" linkID="5530"&gt;MKC-231&lt;/ulink&gt; to produce the peripheral hyperglycemia may be pharmacologically negligible, and the potency to produce the CNS-mediated hyperglycemia is also &amp;gt; 100-fold less than neostigmine. It may therefore suggest that the acute adverse effect of &lt;ulink linkType="Drug" linkID="5530"&gt;MKC-231&lt;/ulink&gt; on peripheral carbohydrate metabolism is pharmacologically negligible [&lt;ulink linkType="reference" linkID="364700"&gt;364700&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Current Opinion &lt;/subtitle&gt;HACU is an important factor in the cholinergic system and has been considered as a regulatory step in ACh synthesis. Deficit in presynaptic choline uptake is one of the features of AD, and is associated with memory and cognitive impairments in AD. Therefore, HACU facilitators such as &lt;ulink linkType="Drug" linkID="5530"&gt;MKC-231&lt;/ulink&gt;, which reverse reduced HACU and increase ACh release and levels in the brain, may theoretically be more efficacious in the treatment of AD. &lt;ulink linkType="Drug" linkID="5530"&gt;MKC-231&lt;/ulink&gt;, a novel HACU enhancer, has attracted some attention because it has significant effects on improving AF64A-induced memory and cognitive deficits, on protecting against glutamate, ionomycin, and AF64A-induced neurotoxicity, and on increasing ACh levels in the brain through the enhancement of HACU. In addition, no toxic effects or significant side effects related to administration of &lt;ulink linkType="Drug" linkID="5530"&gt;MKC-231&lt;/ulink&gt; have so far been reported. &lt;/para&gt;&lt;para&gt;Compared to &lt;ulink linkType="Drug" linkID="4509"&gt;tacrine&lt;/ulink&gt;, an AChE inhibitor, &lt;ulink linkType="Drug" linkID="5530"&gt;MKC-231&lt;/ulink&gt; has a more significant effect on improving the learning deficits in AF64A-treated rats. Therefore, &lt;ulink linkType="Drug" linkID="5530"&gt;MKC-231&lt;/ulink&gt; may be a promising compound for the treatment of AD-type dementia. Although &lt;ulink linkType="Drug" linkID="5530"&gt;MKC-231&lt;/ulink&gt; has been reported to be in phase II Japenese trials [&lt;ulink linkType="reference" linkID="203768"&gt;203768&lt;/ulink&gt;] [&lt;ulink linkType="reference" linkID="348496"&gt;348496&lt;/ulink&gt;] [&lt;ulink linkType="reference" linkID="350686"&gt;350686&lt;/ulink&gt;] [&lt;ulink linkType="reference" linkID="355364"&gt;355364&lt;/ulink&gt;], no data are currently available for evaluating its clinical efficacy. The development of &lt;ulink linkType="Drug" linkID="5530"&gt;MKC-231&lt;/ulink&gt; will depend on its efficacy in clinical trials.&lt;/para&gt;&lt;para&gt;*************************************************************&lt;/para&gt;</ExpertReview><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1015253">BrainCells Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="93">Depression</Indication><StatusDate>2012-05-08T00:00:00.000Z</StatusDate><Source id="1288966" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18229">Mitsubishi-Tokyo Pharmaceuticals Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="14">Alzheimers disease</Indication><StatusDate>2001-03-20T00:00:00.000Z</StatusDate><Source id="400514" type="SERIAL"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20983">Mitsubishi Pharma Corp</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="65">Stroke</Indication><StatusDate>2003-05-12T00:00:00.000Z</StatusDate><Source id="491163" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20300">Takeda Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="14">Alzheimers disease</Indication><StatusDate>2001-03-20T00:00:00.000Z</StatusDate><Source id="400514" type="SERIAL"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20300">Takeda Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="65">Stroke</Indication><StatusDate>2003-05-12T00:00:00.000Z</StatusDate><Source id="491163" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20983">Mitsubishi Pharma Corp</Company><Country id="XW">Western Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="14">Alzheimers disease</Indication><StatusDate>2003-05-12T00:00:00.000Z</StatusDate><Source id="491163" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20300">Takeda Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="15">Amnesia</Indication><StatusDate>2003-05-12T00:00:00.000Z</StatusDate><Source id="491163" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1015253">BrainCells Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="25">Anxiety disorder</Indication><StatusDate>2012-05-08T00:00:00.000Z</StatusDate><Source id="1288966" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18229">Mitsubishi-Tokyo Pharmaceuticals Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="15">Amnesia</Indication><StatusDate>2001-09-13T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1035060">Mitsubishi Tanabe Pharma Corp</Company><Country id="JP">Japan</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="299">Schizophrenia</Indication><StatusDate>2008-05-07T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="1015253">BrainCells Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="25">Anxiety disorder</Indication><StatusDate>2008-04-17T00:00:00.000Z</StatusDate><Source id="897966" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1015253">BrainCells Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="93">Depression</Indication><StatusDate>2008-04-17T00:00:00.000Z</StatusDate><Source id="897966" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20300">Takeda Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="14">Alzheimers disease</Indication><StatusDate>1999-11-25T00:00:00.000Z</StatusDate><Source id="348496" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20983">Mitsubishi Pharma Corp</Company><Country id="XW">Western Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="14">Alzheimers disease</Indication><StatusDate>2001-10-05T00:00:00.000Z</StatusDate><Source id="423717" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20983">Mitsubishi Pharma Corp</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="65">Stroke</Indication><StatusDate>2001-10-05T00:00:00.000Z</StatusDate><Source id="423717" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18229">Mitsubishi-Tokyo Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="14">Alzheimers disease</Indication><StatusDate>2001-03-12T00:00:00.000Z</StatusDate><Source id="400514" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18229">Mitsubishi-Tokyo Pharmaceuticals Inc</Company><Country id="XW">Western Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="14">Alzheimers disease</Indication><StatusDate>2001-03-12T00:00:00.000Z</StatusDate><Source id="400514" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18229">Mitsubishi-Tokyo Pharmaceuticals Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="65">Stroke</Indication><StatusDate>2001-03-12T00:00:00.000Z</StatusDate><Source id="400514" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18229">Mitsubishi-Tokyo Pharmaceuticals Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="CU" sortOrder="9">Clinical</DevelopmentStatus><Indication id="15">Amnesia</Indication><Source id="203768" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18229">Mitsubishi-Tokyo Pharmaceuticals Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="CU" sortOrder="9">Clinical</DevelopmentStatus><Indication id="14">Alzheimers disease</Indication><Source id="203768" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18229">Mitsubishi-Tokyo Pharmaceuticals Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="14">Alzheimers disease</Indication><StatusDate>2000-06-16T00:00:00.000Z</StatusDate><Source id="371091" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20300">Takeda Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="65">Stroke</Indication><StatusDate>2001-03-12T00:00:00.000Z</StatusDate><Source id="400514" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20300">Takeda Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="15">Amnesia</Indication><StatusDate>1999-11-01T00:00:00.000Z</StatusDate><Source id="344071" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20983">Mitsubishi Pharma Corp</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="14">Alzheimers disease</Indication><StatusDate>2001-10-05T00:00:00.000Z</StatusDate><Source id="423717" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20983">Mitsubishi Pharma Corp</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="299">Schizophrenia</Indication><StatusDate>2007-04-27T00:00:00.000Z</StatusDate><Source id="810852" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1015253">BrainCells Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="93">Depression</Indication><StatusDate>2006-08-10T00:00:00.000Z</StatusDate><Source id="810268" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1015253">BrainCells Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="25">Anxiety disorder</Indication><StatusDate>2006-08-10T00:00:00.000Z</StatusDate><Source id="810268" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20300">Takeda Pharmaceutical Co Ltd</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="14">Alzheimers disease</Indication><StatusDate>2001-03-12T00:00:00.000Z</StatusDate><Source id="400514" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20300">Takeda Pharmaceutical Co Ltd</Company><Country id="XW">Western Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="14">Alzheimers disease</Indication><StatusDate>2001-03-12T00:00:00.000Z</StatusDate><Source id="400514" type="SERIAL"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-00131"><Name>AMPA receptor</Name><SwissprotNumbers/></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1015253">BrainCells Inc</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>1</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="1022450">Mitsubishi Chemical Holdings Corp</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>2</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>2</CountTotal></Company><Company><Company id="20300">Takeda Pharmaceutical Co Ltd</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>1</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>0</CountActive><CountInactive>2</CountInactive><CountTotal>2</CountTotal></Type></CountsByTypes><StructureSmiles><Smiles>Cc1c(oc2c1c(c3c(n2)CCCC3)NC(=O)CN4CCCC4=O)C</Smiles></StructureSmiles><Deals><Deal id="109155" title="BrainCells to develop Mitsubishi Pharma's MKC-231 to treat CNS disorders, including mood disorders"/><Deal id="118547" title="Takeda Pharmaceutical and Mitsubishi-Tokyo to codevelop BCI-540"/></Deals><PatentFamilies><PatentFamily id="1461888" number="WO-09609058" title="Remedy and preventive for nervous system disorder."/><PatentFamily id="2027847" number="WO-02085910" title="Polymorph forms of N-(2,3-dimethyl-5,6,7,8-tetrahydrofuro[2,3-b]quinolin-4-yl)-2-(2- oxopyrrolidin -1 -yl)acetamide"/><PatentFamily id="355503" number="WO-2008030651" title="Combinations containing a 4-acylaminopyridine derivative"/><PatentFamily id="658336" number="WO-2004063201" title="Therapeutic agent for schizophrenia"/><PatentFamily id="734789" number="WO-2007092535" title="4-Acylaminopyridine derivative mediated neurogenesis"/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="13">Product (derivative)</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="3">Component of Combination</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>2</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="BrainCells Inc" id="1015253"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Mitsubishi Chemical Holdings Corp" id="1022450"/><CountAsOwner>4</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>4</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></Drug></drugRecordsOutput>